Taiwan Bio Therapeutics Co., Ltd (TPEX: 6892)
Health Care · Biotechnology · TW
NT$25.50
+6.69% today · -21.9% 1Y
Taiwan Bio Therapeutics Co., Ltd (TPEX: 6892) operates in the Biotechnology industry within the Health Care sector. The company is valued at $67.75M and employs 20 people.
Over the last twelve months the share price has lost 21.9%, trading between 23.55 and 33.75.
6892 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $67.75M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.31
- 52-week high
- NT$33.75
- 52-week low
- NT$23.55
- Avg volume (3M)
- —
- Shares outstanding
- 84.61M
- Employees
- 20
- Next earnings
- —
About Taiwan Bio Therapeutics Co., Ltd
Taiwan Bio Therapeutics Co., Ltd. is an enterprise specializing in regenerative medicine, primarily dedicated to the development of novel cellular therapeutics. These advanced treatments are crafted to address a range of medical conditions, including degenerative disorders, cardiovascular ailments, complications stemming from diabetes, and autoimmune diseases. The company was established in 2014 and its operations are headquartered in Taipei City, Taiwan.
- ISIN
- TW0006892003
- Founded
- 2014
- Listed since
- Sep 8, 2022
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.